Contrast-enhanced Ultrasound (CEUS) Manifestation and Histopathological Basis of Parathyroid Glands in Haemodialysis Patients with Secondary Hyperparathyroidism (SHPT) after Cinacalcet Therapy

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900020610

Enrollment

Unknown

Registered

2019-01-10

Start date

2019-06-01

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

secondary hyperparathyroidism

Interventions

Cinacalcet-effective group:Cinacalcet

Control group:No

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. A parent history of renal failure with SHPT; 2. The value of iPTH more than 600pg/ml; 3. With at least one enlarged possible ectopic SHPT nodule disclosed by ultrasound; 4. The 99mTc sestamibi scan showed the nodule had radionuclide concentration on both early and delay phases; 5. All patients receieved PTX.

Exclusion criteria

Exclusion criteria: 1. Allergy to contrast agent; 2. Severe cardiopulmonary dysfunction; 3. Surgical pathology could not be obtained

Design outcomes

Primary

Measure	Time frame
iPTH;Serum calcium;Serum phosphate;ALP;MVD;VEGF;IL;TNF;	—

Countries

China

Contacts

Public ContactMing-an Yu

China-Japan Friendship Hospital

yma301@163.com+86 15010698109

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026